Following a successful first phase during which investigators from Ergon, Imperial, and Queen Mary University of London (QMUL)  discovered a way to reduce inflammation in autoimmune diseases by taking advantage of metabolic pathways of pro-inflammatory macrophages, Ergon and Imperial plan to expand their collaboration to include development of drug candidates based on targets identified through a systems biology approach in Dr. Behmoaras’ lab.